• 23 February 2017
    Axonics Granted Four U.S. Patents Related to its Implantable Sacral Neuromodulation Technology

    Axonics Modulation Technologies, Inc., developer of the first rechargeable Sacral Neuromodulation (r-SNM™) system for the treatment of urinary and fecal dysfunction, announced today that the United States Patent and Trademark Office has granted Axonics four new U.S. patents relating to its implantable sacral neuromodulation technology.

    • US 9,555,246 and US 9,561,372 relate to an integrated electromyography (EMG) technology that aids in accurate placement during the lead implantation procedure.
    • US 9,533,155 relates to an electrode recommendation engine simplifying the programming of stimulation therapy.
    • US 9,517,338 relates to a multichannel stimulation lead test clip improving ease of use during the lead implantation procedure.

    “The diverse and rapid expansion of the Axonics U.S. patent portfolio further demonstrates the level of innovation applied by our Company in addressing the unmet needs of clinicians and patients relating to implantable Sacral Neuromodulation. With these four new U.S. patents, we now have 73 granted and 78 pending patent applications in our portfolio in various jurisdictions around the world,” said Raymond W. Cohen, Axonics Chief Executive Officer.

    The Axonics patent portfolio represents technology internally developed by Axonics and under license from the Alfred Mann Foundation.

    The Axonics r-SNM System® received European CE Mark approval in June 2016 and Health Canada approval in December 2016 for the treatment of overactive bladder (including urinary urge incontinence and urinary urgency-frequency), urinary retention, and fecal incontinence.

    The Company has completed enrollment of its RELAX-OAB multi-center post-market clinical study for patients with overactive bladder in select centers in the Netherlands, Belgium, France and the UK.

    Axonics anticipates initiating a U.S. FDA pivotal clinical study for overactive bladder patients in select centers in the U.S., Canada and Europe in the second half of 2017.